STOCK TITAN

[424B3] Medicus Pharma Ltd. Prospectus Filed Pursuant to Rule 424(b)(3)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
424B3
Rhea-AI Filing Summary

Collective Audience Inc. ("CAUD") has filed a Preliminary Proxy Statement (Form PREM14A) seeking stockholder approval for a transformative divestiture. The Company proposes to sell 100% of The Odyssey S.A.S. (dba “BeOp”) and its 51% interest in DSL Digital LLC to NYIAX Marketing and Advertising Solutions, Inc., a wholly-owned subsidiary of NYIAX, Inc. Gregg Greenberg, the remaining 49% owner of DSL, will concurrently sell his interest. The transaction (the “Subsidiary Sale”) constitutes the disposition of substantially all of CAUD’s operating assets other than the DLQ business unit.

Consideration structure. NYIAX will issue shares equal to 49% of its fully-diluted common stock post-closing (“Consideration Shares”). Allocation:

  • CAUD – 71.63% of Consideration Shares (35.1% of NYIAX on a fully-diluted basis)
  • Gregg Greenberg – 18.37% (9% of NYIAX fully-diluted)
  • 10% escrowed as Holdback Shares for indemnification.
No cash proceeds are involved. The Consideration Shares are subject to (i) a two-year/183-day lock-up (whichever ends earlier or upon NYIAX IPO consent) and (ii) a 10% indemnity holdback.

Key proposals and vote requirements. Stockholders will vote on (1) approval of the Subsidiary Sale and (2) authority to adjourn the meeting to solicit additional proxies if necessary. Proposal 1 requires affirmative votes from a majority of all outstanding CAUD common shares; abstentions, failures to vote, and broker non-votes count as “AGAINST.” Proposal 2 requires a majority of votes cast.

Strategic rationale. The Board cites persistent operating losses, limited access to capital, overlapping technology with NYIAX, and the opportunity to relieve CAUD of BeOp and DSL liabilities while retaining upside through an equity stake in NYIAX. The Board unanimously recommends voting “FOR” both proposals.

Principal terms and conditions. Closing is targeted for Q3 2025, subject to extensive mutual representations, regulatory and third-party consents, no material adverse changes, and satisfactory completion of due diligence. The agreement contains a strict no-solicitation clause and provides customary termination rights, including a July 31 2025 outside date. A two-year survival period applies to most reps & warranties; indemnity claims are capped by the 10% share holdback.

Risks highlighted. • Uncertainty in valuing illiquid NYIAX stock. • No immediate cash inflow to fund residual DLQ operations. • Lock-up limits liquidity. • Failure to obtain stockholder approval or satisfy closing conditions terminates the deal, potentially harming CAUD’s financial position. • CAUD forfeits future upside from BeOp and DSL beyond its indirect NYIAX stake.

Collective Audience Inc. ("CAUD") ha presentato una Dichiarazione Preliminare di Procura (Modulo PREM14A) per ottenere l'approvazione degli azionisti su una cessione trasformativa. La Società propone di vendere il 100% di The Odyssey S.A.S. (operante come “BeOp”) e il 51% della sua partecipazione in DSL Digital LLC a NYIAX Marketing and Advertising Solutions, Inc., una controllata interamente posseduta da NYIAX, Inc. Gregg Greenberg, proprietario del restante 49% di DSL, venderà contestualmente la sua quota. La transazione (la “Cessione della Controllata”) rappresenta la cessione di sostanzialmente tutti gli asset operativi di CAUD, ad eccezione dell’unità di business DLQ.

Struttura della controprestazione. NYIAX emetterà azioni pari al 49% del suo capitale ordinario totalmente diluito post-closing (“Azioni di Controprestazione”). Distribuzione:

  • CAUD – 71,63% delle Azioni di Controprestazione (35,1% di NYIAX su base totalmente diluita)
  • Gregg Greenberg – 18,37% (9% di NYIAX totalmente diluito)
  • 10% bloccato come Azioni di Garanzia per indennizzi.
Non sono previsti incassi in contanti. Le Azioni di Controprestazione sono soggette a (i) un lock-up di due anni o 183 giorni (quanto prima o previo consenso IPO NYIAX) e (ii) un blocco del 10% per indennità.

Proposte chiave e requisiti di voto. Gli azionisti voteranno su (1) l’approvazione della Cessione della Controllata e (2) l’autorizzazione a rinviare l’assemblea per raccogliere ulteriori deleghe, se necessario. La proposta 1 richiede il voto favorevole della maggioranza di tutte le azioni ordinarie CAUD in circolazione; astensioni, mancati voti e voti di broker non contano come "CONTRARI". La proposta 2 richiede la maggioranza dei voti espressi.

Motivazioni strategiche. Il Consiglio evidenzia perdite operative persistenti, accesso limitato al capitale, tecnologia sovrapposta con NYIAX e l’opportunità di liberare CAUD dalle passività di BeOp e DSL mantenendo un potenziale di crescita tramite la partecipazione azionaria in NYIAX. Il Consiglio raccomanda all’unanimità di votare "A FAVORE" di entrambe le proposte.

Termini e condizioni principali. La chiusura è prevista per il terzo trimestre 2025, subordinata a numerose dichiarazioni reciproche, consensi regolamentari e di terzi, assenza di cambiamenti materiali avversi e completamento soddisfacente della due diligence. L’accordo include una rigorosa clausola di non sollecitazione e prevede diritti di recesso consueti, incluso un termine esterno al 31 luglio 2025. La maggior parte delle dichiarazioni e garanzie ha una durata di due anni; le richieste di indennizzo sono limitate al blocco del 10% delle azioni.

Rischi evidenziati. • Incertezza nella valutazione delle azioni illiquide NYIAX. • Nessun flusso di cassa immediato per finanziare le operazioni residue di DLQ. • Il lock-up limita la liquidità. • Il mancato ottenimento dell’approvazione degli azionisti o il mancato soddisfacimento delle condizioni di chiusura annulla l’accordo, potenzialmente danneggiando la posizione finanziaria di CAUD. • CAUD rinuncia a potenziali guadagni futuri da BeOp e DSL oltre la sua partecipazione indiretta in NYIAX.

Collective Audience Inc. ("CAUD") ha presentado una Declaración Preliminar de Poder (Formulario PREM14A) solicitando la aprobación de los accionistas para una desinversión transformadora. La Compañía propone vender el 100% de The Odyssey S.A.S. (operando como “BeOp”) y su participación del 51% en DSL Digital LLC a NYIAX Marketing and Advertising Solutions, Inc., una subsidiaria de propiedad total de NYIAX, Inc. Gregg Greenberg, propietario del 49% restante de DSL, venderá simultáneamente su participación. La transacción (la “Venta de la Subsidiaria”) constituye la disposición de prácticamente todos los activos operativos de CAUD, excepto la unidad de negocio DLQ.

Estructura de la contraprestación. NYIAX emitirá acciones equivalentes al 49% de su capital social totalmente diluido después del cierre (“Acciones de Contraprestación”). Distribución:

  • CAUD – 71,63% de las Acciones de Contraprestación (35,1% de NYIAX en base totalmente diluida)
  • Gregg Greenberg – 18,37% (9% de NYIAX totalmente diluido)
  • 10% en custodia como Acciones de Retención para indemnización.
No se involucran ingresos en efectivo. Las Acciones de Contraprestación están sujetas a (i) un bloqueo de dos años o 183 días (lo que ocurra primero o con consentimiento de la IPO de NYIAX) y (ii) una retención del 10% para indemnización.

Propuestas clave y requisitos de voto. Los accionistas votarán sobre (1) la aprobación de la Venta de la Subsidiaria y (2) la autoridad para aplazar la reunión para solicitar más poderes si es necesario. La propuesta 1 requiere votos afirmativos de la mayoría de todas las acciones ordinarias en circulación de CAUD; las abstenciones, la falta de voto y los votos de corredores se cuentan como "EN CONTRA". La propuesta 2 requiere mayoría de votos emitidos.

Justificación estratégica. La Junta señala pérdidas operativas persistentes, acceso limitado a capital, tecnología superpuesta con NYIAX y la oportunidad de liberar a CAUD de las responsabilidades de BeOp y DSL mientras mantiene potencial de crecimiento mediante una participación accionaria en NYIAX. La Junta recomienda unánimemente votar "A FAVOR" de ambas propuestas.

Términos y condiciones principales. El cierre está previsto para el tercer trimestre de 2025, sujeto a extensas representaciones mutuas, consentimientos regulatorios y de terceros, ausencia de cambios adversos materiales y finalización satisfactoria de la diligencia debida. El acuerdo incluye una estricta cláusula de no solicitación y proporciona derechos de terminación habituales, incluyendo una fecha límite externa del 31 de julio de 2025. La mayoría de las declaraciones y garantías tienen un período de vigencia de dos años; las reclamaciones de indemnización están limitadas por la retención del 10% de acciones.

Riesgos destacados. • Incertidumbre en la valoración de las acciones ilíquidas de NYIAX. • No hay entrada inmediata de efectivo para financiar las operaciones residuales de DLQ. • El bloqueo limita la liquidez. • La falta de aprobación de los accionistas o el incumplimiento de las condiciones de cierre termina el acuerdo, lo que podría perjudicar la posición financiera de CAUD. • CAUD renuncia a futuras ganancias de BeOp y DSL más allá de su participación indirecta en NYIAX.

Collective Audience Inc.("CAUD")는 주주 승인 확보를 위해 예비 위임장 성명서(Form PREM14A)를 제출했습니다. 회사는 The Odyssey S.A.S.(“BeOp”으로 영업)와 DSL Digital LLC의 51% 지분 전부를 NYIAX, Inc.의 전액 출자 자회사인 NYIAX Marketing and Advertising Solutions, Inc.에 매각할 계획입니다. DSL의 나머지 49% 소유주인 Gregg Greenberg도 동시에 자신의 지분을 매각합니다. 이 거래(“자회사 매각”)는 DLQ 사업부를 제외한 CAUD의 거의 모든 영업 자산 처분에 해당합니다.

대가 구조. NYIAX는 거래 종료 후 완전 희석 기준으로 49%에 해당하는 보통주를 발행합니다(“대가 주식”). 배분:

  • CAUD – 대가 주식의 71.63% (완전 희석 기준 NYIAX의 35.1%)
  • Gregg Greenberg – 18.37% (완전 희석 기준 NYIAX의 9%)
  • 10%는 보증금으로 보류되어 배상금으로 사용됩니다.
현금 수익은 없습니다. 대가 주식은 (i) 2년 또는 183일(더 빠른 시점 또는 NYIAX IPO 동의 시) 락업과 (ii) 10% 배상금 보류 조건이 적용됩니다.

주요 제안 및 투표 요건. 주주들은 (1) 자회사 매각 승인과 (2) 필요시 추가 위임장 확보를 위한 회의 연기 권한에 대해 투표합니다. 제안 1은 CAUD 발행 보통주 과반수 찬성이 필요하며, 기권, 무투표, 중개인 무투표는 "반대"로 간주됩니다. 제안 2는 투표된 과반수 찬성이 필요합니다.

전략적 이유. 이사회는 지속적인 영업 손실, 제한된 자본 접근성, NYIAX와 중복되는 기술, BeOp 및 DSL 부채에서 CAUD를 해방시키면서 NYIAX 지분을 통한 성장 가능성을 유지할 기회를 들고 있습니다. 이사회는 두 제안 모두에 대해 만장일치로 "찬성"을 권고합니다.

주요 조건. 거래 종료는 2025년 3분기를 목표로 하며, 상호 진술, 규제 및 제3자 동의, 중대한 악영향 변화 없음, 실사 완료 등을 조건으로 합니다. 계약에는 엄격한 비유인 조항과 2025년 7월 31일 외부 종료일 포함 일반적인 계약 해지 권리가 포함됩니다. 대부분의 진술 및 보증은 2년간 유효하며, 배상 청구는 10% 주식 보류 한도로 제한됩니다.

강조된 위험. • 비유동 NYIAX 주식 평가의 불확실성. • DLQ 잔여 운영에 즉각적인 현금 유입 없음. • 락업으로 유동성 제한. • 주주 승인 실패 또는 종료 조건 미충족 시 거래 종료로 CAUD 재무 상태 악화 가능성. • CAUD는 NYIAX 간접 지분 외 BeOp 및 DSL의 향후 상승 잠재력을 포기합니다.

Collective Audience Inc. (« CAUD ») a déposé une déclaration préliminaire de procuration (formulaire PREM14A) sollicitant l'approbation des actionnaires pour une cession transformative. La société propose de vendre 100 % de The Odyssey S.A.S. (exerçant sous le nom de « BeOp ») et sa participation de 51 % dans DSL Digital LLC à NYIAX Marketing and Advertising Solutions, Inc., une filiale en propriété exclusive de NYIAX, Inc. Gregg Greenberg, propriétaire des 49 % restants de DSL, vendra simultanément sa participation. La transaction (la « Vente de la Filiale ») constitue la cession de pratiquement tous les actifs opérationnels de CAUD à l'exception de l'unité commerciale DLQ.

Structure de la contrepartie. NYIAX émettra des actions équivalant à 49 % de son capital social entièrement dilué après clôture (« Actions de Contrepartie »). Répartition :

  • CAUD – 71,63 % des Actions de Contrepartie (35,1 % de NYIAX sur une base entièrement diluée)
  • Gregg Greenberg – 18,37 % (9 % de NYIAX entièrement dilué)
  • 10 % en séquestre en tant qu'Actions de Garantie pour indemnisation.
Aucun produit en espèces n'est impliqué. Les Actions de Contrepartie sont soumises à (i) une période de blocage de deux ans ou 183 jours (selon la première éventualité ou avec le consentement de l'IPO de NYIAX) et (ii) une retenue de 10 % pour indemnisation.

Propositions clés et exigences de vote. Les actionnaires voteront sur (1) l'approbation de la Vente de la Filiale et (2) l'autorisation de reporter la réunion pour solliciter des procurations supplémentaires si nécessaire. La proposition 1 nécessite des votes favorables de la majorité de toutes les actions ordinaires en circulation de CAUD ; les abstentions, les votes non exprimés et les votes des courtiers sont comptés comme « CONTRE ». La proposition 2 nécessite la majorité des votes exprimés.

Justification stratégique. Le conseil cite des pertes d'exploitation persistantes, un accès limité au capital, une technologie redondante avec NYIAX et l'opportunité de libérer CAUD des passifs de BeOp et DSL tout en conservant un potentiel de croissance via une participation dans NYIAX. Le conseil recommande à l'unanimité de voter « POUR » les deux propositions.

Principaux termes et conditions. La clôture est prévue pour le troisième trimestre 2025, sous réserve de nombreuses déclarations réciproques, consentements réglementaires et tiers, absence de changements défavorables importants et achèvement satisfaisant de la diligence raisonnable. L'accord contient une clause stricte de non-sollicitation et prévoit des droits de résiliation habituels, y compris une date limite externe au 31 juillet 2025. La plupart des déclarations et garanties ont une durée de deux ans ; les demandes d'indemnisation sont plafonnées par la retenue de 10 % des actions.

Risques soulignés. • Incertitude dans l'évaluation des actions illiquides de NYIAX. • Aucun flux de trésorerie immédiat pour financer les opérations résiduelles de DLQ. • Le blocage limite la liquidité. • L'échec à obtenir l'approbation des actionnaires ou à remplir les conditions de clôture entraîne la résiliation de l'accord, ce qui pourrait nuire à la situation financière de CAUD. • CAUD renonce à un potentiel de plus-value futur de BeOp et DSL au-delà de sa participation indirecte dans NYIAX.

Collective Audience Inc. ("CAUD") hat eine vorläufige Vollmachtsmitteilung (Formular PREM14A) eingereicht, um die Zustimmung der Aktionäre für eine transformative Veräußerung zu erhalten. Das Unternehmen beabsichtigt, 100 % von The Odyssey S.A.S. (geschäftlich als „BeOp“ tätig) und seinen 51 % Anteil an DSL Digital LLC an NYIAX Marketing and Advertising Solutions, Inc., eine hundertprozentige Tochtergesellschaft von NYIAX, Inc., zu verkaufen. Gregg Greenberg, der verbleibende 49%-Eigentümer von DSL, wird gleichzeitig seinen Anteil verkaufen. Die Transaktion (der „Tochtergesellschaftsverkauf“) stellt die Veräußerung von im Wesentlichen allen operativen Vermögenswerten von CAUD dar, mit Ausnahme der Geschäftseinheit DLQ.

Struktur der Gegenleistung. NYIAX wird nach Abschluss Aktien ausgeben, die 49 % seines vollständig verwässerten Stammkapitals entsprechen („Gegenleistungsaktien“). Aufteilung:

  • CAUD – 71,63 % der Gegenleistungsaktien (35,1 % von NYIAX auf vollständig verwässerter Basis)
  • Gregg Greenberg – 18,37 % (9 % von NYIAX vollständig verwässert)
  • 10 % werden als Rückbehaltungsaktien zur Schadensersatzsicherung treuhänderisch gehalten.
Es gibt keinen Barauszahlungserlös. Die Gegenleistungsaktien unterliegen (i) einer Sperrfrist von zwei Jahren oder 183 Tagen (je nachdem, was früher endet oder mit Zustimmung des NYIAX-IPO) und (ii) einer 10 %igen Schadensersatzrückbehaltung.

Wesentliche Vorschläge und Abstimmungsanforderungen. Die Aktionäre stimmen über (1) die Genehmigung des Tochtergesellschaftsverkaufs und (2) die Befugnis zur Vertagung der Versammlung zur Einholung weiterer Vollmachten ab, falls erforderlich. Vorschlag 1 erfordert die Zustimmung der Mehrheit aller ausstehenden CAUD-Stammaktien; Enthaltungen, Nichtabstimmungen und Broker-Non-Votes werden als „GEGEN“ gezählt. Vorschlag 2 erfordert die Mehrheit der abgegebenen Stimmen.

Strategische Begründung. Der Vorstand nennt anhaltende operative Verluste, begrenzten Kapitalzugang, überlappende Technologie mit NYIAX und die Möglichkeit, CAUD von BeOp- und DSL-Verbindlichkeiten zu entlasten und gleichzeitig durch eine Beteiligung an NYIAX Aufwärtspotenzial zu behalten. Der Vorstand empfiehlt einstimmig, beiden Vorschlägen "ZUZUSTIMMEN".

Hauptbedingungen. Der Abschluss ist für das dritte Quartal 2025 geplant und unterliegt umfangreichen gegenseitigen Zusicherungen, behördlichen und Drittzustimmungen, dem Fehlen wesentlicher nachteiliger Veränderungen und einer zufriedenstellenden Durchführung der Due Diligence. Die Vereinbarung enthält eine strenge No-Solicitation-Klausel und sieht übliche Kündigungsrechte vor, einschließlich eines Außerkrafttretensdatums am 31. Juli 2025. Die meisten Zusicherungen und Gewährleistungen gelten für zwei Jahre; Schadensersatzansprüche sind durch die 10 %ige Aktienrückbehaltung begrenzt.

Hervorgehobene Risiken. • Unsicherheit bei der Bewertung der illiquiden NYIAX-Aktien. • Kein sofortiger Geldzufluss zur Finanzierung der verbleibenden DLQ-Geschäfte. • Sperrfrist begrenzt Liquidität. • Das Scheitern der Aktionärszustimmung oder der Erfüllung der Abschlussbedingungen beendet das Geschäft und könnte die finanzielle Lage von CAUD beeinträchtigen. • CAUD verzichtet auf zukünftiges Aufwärtspotenzial von BeOp und DSL über seine indirekte Beteiligung an NYIAX hinaus.

Positive
  • Liability relief: CAUD sheds BeOp and DSL obligations, potentially improving its balance sheet.
  • Meaningful equity upside: 35.1% fully-diluted stake in NYIAX offers participation in a larger combined ad-tech platform.
  • Board unanimity: Full director support may facilitate proxy passage and demonstrates strategic alignment.
  • Standard protections: Escrow, lock-ups, and detailed closing conditions lower post-closing dispute risk.
Negative
  • No cash proceeds: CAUD receives only restricted stock, limiting near-term liquidity.
  • Voting hurdle: Majority of all outstanding shares must approve; non-votes count against, elevating deal risk.
  • Lock-up & holdback: Up to two-year trading restriction and 10% escrow delay monetization.
  • Valuation uncertainty: NYIAX shares are private and unpriced; future market value is unknown.
  • No-solicitation clause: Limits CAUD’s ability to entertain potentially superior offers.

Insights

TL;DR: Divestiture swaps risky assets for sizable NYIAX stake, removes liabilities, and may reset CAUD’s strategy—overall positive but dependent on NYIAX execution.

The sale off-loads two capital- intensive subsidiaries and their contingent obligations while granting CAUD 35.1% fully-diluted ownership of NYIAX. Because NYIAX is private and positioning for an IPO, the equity could re-rate meaningfully, offering asymmetric upside relative to CAUD’s current OTC-traded valuation. The lock-up and indemnity escrow are standard protections that also signal NYIAX’s confidence. Eliminating BeOp/DSL liabilities should simplify CAUD’s balance sheet and free management to focus on the DLQ unit or other strategic alternatives. Board unanimity and detailed closing conditions suggest high deal integrity, though the majority-of-outstanding vote threshold remains a hurdle. On balance, I view the transaction as value-accretive for long-term holders.

TL;DR: No-cash structure, illiquid consideration, and stringent lock-ups expose CAUD investors to execution and valuation risk—impact neutral to negative.

Shareholders exchange operating assets for restricted NYIAX stock without cash proceeds, leaving CAUD reliant on an unlisted company’s future capital events for liquidity. The two-year or IPO-triggered lock-up, plus a 10% escrow, delays monetization. Inability to solicit superior proposals and absence of a fiduciary-out clause limit optionality. Should NYIAX underperform or an IPO be postponed, CAUD could face funding pressure to support DLQ while its principal asset remains non-tradable. Given these uncertainties and the high voting hurdle, I classify the announcement as carrying considerable downside risk offsetting potential gains.

Collective Audience Inc. ("CAUD") ha presentato una Dichiarazione Preliminare di Procura (Modulo PREM14A) per ottenere l'approvazione degli azionisti su una cessione trasformativa. La Società propone di vendere il 100% di The Odyssey S.A.S. (operante come “BeOp”) e il 51% della sua partecipazione in DSL Digital LLC a NYIAX Marketing and Advertising Solutions, Inc., una controllata interamente posseduta da NYIAX, Inc. Gregg Greenberg, proprietario del restante 49% di DSL, venderà contestualmente la sua quota. La transazione (la “Cessione della Controllata”) rappresenta la cessione di sostanzialmente tutti gli asset operativi di CAUD, ad eccezione dell’unità di business DLQ.

Struttura della controprestazione. NYIAX emetterà azioni pari al 49% del suo capitale ordinario totalmente diluito post-closing (“Azioni di Controprestazione”). Distribuzione:

  • CAUD – 71,63% delle Azioni di Controprestazione (35,1% di NYIAX su base totalmente diluita)
  • Gregg Greenberg – 18,37% (9% di NYIAX totalmente diluito)
  • 10% bloccato come Azioni di Garanzia per indennizzi.
Non sono previsti incassi in contanti. Le Azioni di Controprestazione sono soggette a (i) un lock-up di due anni o 183 giorni (quanto prima o previo consenso IPO NYIAX) e (ii) un blocco del 10% per indennità.

Proposte chiave e requisiti di voto. Gli azionisti voteranno su (1) l’approvazione della Cessione della Controllata e (2) l’autorizzazione a rinviare l’assemblea per raccogliere ulteriori deleghe, se necessario. La proposta 1 richiede il voto favorevole della maggioranza di tutte le azioni ordinarie CAUD in circolazione; astensioni, mancati voti e voti di broker non contano come "CONTRARI". La proposta 2 richiede la maggioranza dei voti espressi.

Motivazioni strategiche. Il Consiglio evidenzia perdite operative persistenti, accesso limitato al capitale, tecnologia sovrapposta con NYIAX e l’opportunità di liberare CAUD dalle passività di BeOp e DSL mantenendo un potenziale di crescita tramite la partecipazione azionaria in NYIAX. Il Consiglio raccomanda all’unanimità di votare "A FAVORE" di entrambe le proposte.

Termini e condizioni principali. La chiusura è prevista per il terzo trimestre 2025, subordinata a numerose dichiarazioni reciproche, consensi regolamentari e di terzi, assenza di cambiamenti materiali avversi e completamento soddisfacente della due diligence. L’accordo include una rigorosa clausola di non sollecitazione e prevede diritti di recesso consueti, incluso un termine esterno al 31 luglio 2025. La maggior parte delle dichiarazioni e garanzie ha una durata di due anni; le richieste di indennizzo sono limitate al blocco del 10% delle azioni.

Rischi evidenziati. • Incertezza nella valutazione delle azioni illiquide NYIAX. • Nessun flusso di cassa immediato per finanziare le operazioni residue di DLQ. • Il lock-up limita la liquidità. • Il mancato ottenimento dell’approvazione degli azionisti o il mancato soddisfacimento delle condizioni di chiusura annulla l’accordo, potenzialmente danneggiando la posizione finanziaria di CAUD. • CAUD rinuncia a potenziali guadagni futuri da BeOp e DSL oltre la sua partecipazione indiretta in NYIAX.

Collective Audience Inc. ("CAUD") ha presentado una Declaración Preliminar de Poder (Formulario PREM14A) solicitando la aprobación de los accionistas para una desinversión transformadora. La Compañía propone vender el 100% de The Odyssey S.A.S. (operando como “BeOp”) y su participación del 51% en DSL Digital LLC a NYIAX Marketing and Advertising Solutions, Inc., una subsidiaria de propiedad total de NYIAX, Inc. Gregg Greenberg, propietario del 49% restante de DSL, venderá simultáneamente su participación. La transacción (la “Venta de la Subsidiaria”) constituye la disposición de prácticamente todos los activos operativos de CAUD, excepto la unidad de negocio DLQ.

Estructura de la contraprestación. NYIAX emitirá acciones equivalentes al 49% de su capital social totalmente diluido después del cierre (“Acciones de Contraprestación”). Distribución:

  • CAUD – 71,63% de las Acciones de Contraprestación (35,1% de NYIAX en base totalmente diluida)
  • Gregg Greenberg – 18,37% (9% de NYIAX totalmente diluido)
  • 10% en custodia como Acciones de Retención para indemnización.
No se involucran ingresos en efectivo. Las Acciones de Contraprestación están sujetas a (i) un bloqueo de dos años o 183 días (lo que ocurra primero o con consentimiento de la IPO de NYIAX) y (ii) una retención del 10% para indemnización.

Propuestas clave y requisitos de voto. Los accionistas votarán sobre (1) la aprobación de la Venta de la Subsidiaria y (2) la autoridad para aplazar la reunión para solicitar más poderes si es necesario. La propuesta 1 requiere votos afirmativos de la mayoría de todas las acciones ordinarias en circulación de CAUD; las abstenciones, la falta de voto y los votos de corredores se cuentan como "EN CONTRA". La propuesta 2 requiere mayoría de votos emitidos.

Justificación estratégica. La Junta señala pérdidas operativas persistentes, acceso limitado a capital, tecnología superpuesta con NYIAX y la oportunidad de liberar a CAUD de las responsabilidades de BeOp y DSL mientras mantiene potencial de crecimiento mediante una participación accionaria en NYIAX. La Junta recomienda unánimemente votar "A FAVOR" de ambas propuestas.

Términos y condiciones principales. El cierre está previsto para el tercer trimestre de 2025, sujeto a extensas representaciones mutuas, consentimientos regulatorios y de terceros, ausencia de cambios adversos materiales y finalización satisfactoria de la diligencia debida. El acuerdo incluye una estricta cláusula de no solicitación y proporciona derechos de terminación habituales, incluyendo una fecha límite externa del 31 de julio de 2025. La mayoría de las declaraciones y garantías tienen un período de vigencia de dos años; las reclamaciones de indemnización están limitadas por la retención del 10% de acciones.

Riesgos destacados. • Incertidumbre en la valoración de las acciones ilíquidas de NYIAX. • No hay entrada inmediata de efectivo para financiar las operaciones residuales de DLQ. • El bloqueo limita la liquidez. • La falta de aprobación de los accionistas o el incumplimiento de las condiciones de cierre termina el acuerdo, lo que podría perjudicar la posición financiera de CAUD. • CAUD renuncia a futuras ganancias de BeOp y DSL más allá de su participación indirecta en NYIAX.

Collective Audience Inc.("CAUD")는 주주 승인 확보를 위해 예비 위임장 성명서(Form PREM14A)를 제출했습니다. 회사는 The Odyssey S.A.S.(“BeOp”으로 영업)와 DSL Digital LLC의 51% 지분 전부를 NYIAX, Inc.의 전액 출자 자회사인 NYIAX Marketing and Advertising Solutions, Inc.에 매각할 계획입니다. DSL의 나머지 49% 소유주인 Gregg Greenberg도 동시에 자신의 지분을 매각합니다. 이 거래(“자회사 매각”)는 DLQ 사업부를 제외한 CAUD의 거의 모든 영업 자산 처분에 해당합니다.

대가 구조. NYIAX는 거래 종료 후 완전 희석 기준으로 49%에 해당하는 보통주를 발행합니다(“대가 주식”). 배분:

  • CAUD – 대가 주식의 71.63% (완전 희석 기준 NYIAX의 35.1%)
  • Gregg Greenberg – 18.37% (완전 희석 기준 NYIAX의 9%)
  • 10%는 보증금으로 보류되어 배상금으로 사용됩니다.
현금 수익은 없습니다. 대가 주식은 (i) 2년 또는 183일(더 빠른 시점 또는 NYIAX IPO 동의 시) 락업과 (ii) 10% 배상금 보류 조건이 적용됩니다.

주요 제안 및 투표 요건. 주주들은 (1) 자회사 매각 승인과 (2) 필요시 추가 위임장 확보를 위한 회의 연기 권한에 대해 투표합니다. 제안 1은 CAUD 발행 보통주 과반수 찬성이 필요하며, 기권, 무투표, 중개인 무투표는 "반대"로 간주됩니다. 제안 2는 투표된 과반수 찬성이 필요합니다.

전략적 이유. 이사회는 지속적인 영업 손실, 제한된 자본 접근성, NYIAX와 중복되는 기술, BeOp 및 DSL 부채에서 CAUD를 해방시키면서 NYIAX 지분을 통한 성장 가능성을 유지할 기회를 들고 있습니다. 이사회는 두 제안 모두에 대해 만장일치로 "찬성"을 권고합니다.

주요 조건. 거래 종료는 2025년 3분기를 목표로 하며, 상호 진술, 규제 및 제3자 동의, 중대한 악영향 변화 없음, 실사 완료 등을 조건으로 합니다. 계약에는 엄격한 비유인 조항과 2025년 7월 31일 외부 종료일 포함 일반적인 계약 해지 권리가 포함됩니다. 대부분의 진술 및 보증은 2년간 유효하며, 배상 청구는 10% 주식 보류 한도로 제한됩니다.

강조된 위험. • 비유동 NYIAX 주식 평가의 불확실성. • DLQ 잔여 운영에 즉각적인 현금 유입 없음. • 락업으로 유동성 제한. • 주주 승인 실패 또는 종료 조건 미충족 시 거래 종료로 CAUD 재무 상태 악화 가능성. • CAUD는 NYIAX 간접 지분 외 BeOp 및 DSL의 향후 상승 잠재력을 포기합니다.

Collective Audience Inc. (« CAUD ») a déposé une déclaration préliminaire de procuration (formulaire PREM14A) sollicitant l'approbation des actionnaires pour une cession transformative. La société propose de vendre 100 % de The Odyssey S.A.S. (exerçant sous le nom de « BeOp ») et sa participation de 51 % dans DSL Digital LLC à NYIAX Marketing and Advertising Solutions, Inc., une filiale en propriété exclusive de NYIAX, Inc. Gregg Greenberg, propriétaire des 49 % restants de DSL, vendra simultanément sa participation. La transaction (la « Vente de la Filiale ») constitue la cession de pratiquement tous les actifs opérationnels de CAUD à l'exception de l'unité commerciale DLQ.

Structure de la contrepartie. NYIAX émettra des actions équivalant à 49 % de son capital social entièrement dilué après clôture (« Actions de Contrepartie »). Répartition :

  • CAUD – 71,63 % des Actions de Contrepartie (35,1 % de NYIAX sur une base entièrement diluée)
  • Gregg Greenberg – 18,37 % (9 % de NYIAX entièrement dilué)
  • 10 % en séquestre en tant qu'Actions de Garantie pour indemnisation.
Aucun produit en espèces n'est impliqué. Les Actions de Contrepartie sont soumises à (i) une période de blocage de deux ans ou 183 jours (selon la première éventualité ou avec le consentement de l'IPO de NYIAX) et (ii) une retenue de 10 % pour indemnisation.

Propositions clés et exigences de vote. Les actionnaires voteront sur (1) l'approbation de la Vente de la Filiale et (2) l'autorisation de reporter la réunion pour solliciter des procurations supplémentaires si nécessaire. La proposition 1 nécessite des votes favorables de la majorité de toutes les actions ordinaires en circulation de CAUD ; les abstentions, les votes non exprimés et les votes des courtiers sont comptés comme « CONTRE ». La proposition 2 nécessite la majorité des votes exprimés.

Justification stratégique. Le conseil cite des pertes d'exploitation persistantes, un accès limité au capital, une technologie redondante avec NYIAX et l'opportunité de libérer CAUD des passifs de BeOp et DSL tout en conservant un potentiel de croissance via une participation dans NYIAX. Le conseil recommande à l'unanimité de voter « POUR » les deux propositions.

Principaux termes et conditions. La clôture est prévue pour le troisième trimestre 2025, sous réserve de nombreuses déclarations réciproques, consentements réglementaires et tiers, absence de changements défavorables importants et achèvement satisfaisant de la diligence raisonnable. L'accord contient une clause stricte de non-sollicitation et prévoit des droits de résiliation habituels, y compris une date limite externe au 31 juillet 2025. La plupart des déclarations et garanties ont une durée de deux ans ; les demandes d'indemnisation sont plafonnées par la retenue de 10 % des actions.

Risques soulignés. • Incertitude dans l'évaluation des actions illiquides de NYIAX. • Aucun flux de trésorerie immédiat pour financer les opérations résiduelles de DLQ. • Le blocage limite la liquidité. • L'échec à obtenir l'approbation des actionnaires ou à remplir les conditions de clôture entraîne la résiliation de l'accord, ce qui pourrait nuire à la situation financière de CAUD. • CAUD renonce à un potentiel de plus-value futur de BeOp et DSL au-delà de sa participation indirecte dans NYIAX.

Collective Audience Inc. ("CAUD") hat eine vorläufige Vollmachtsmitteilung (Formular PREM14A) eingereicht, um die Zustimmung der Aktionäre für eine transformative Veräußerung zu erhalten. Das Unternehmen beabsichtigt, 100 % von The Odyssey S.A.S. (geschäftlich als „BeOp“ tätig) und seinen 51 % Anteil an DSL Digital LLC an NYIAX Marketing and Advertising Solutions, Inc., eine hundertprozentige Tochtergesellschaft von NYIAX, Inc., zu verkaufen. Gregg Greenberg, der verbleibende 49%-Eigentümer von DSL, wird gleichzeitig seinen Anteil verkaufen. Die Transaktion (der „Tochtergesellschaftsverkauf“) stellt die Veräußerung von im Wesentlichen allen operativen Vermögenswerten von CAUD dar, mit Ausnahme der Geschäftseinheit DLQ.

Struktur der Gegenleistung. NYIAX wird nach Abschluss Aktien ausgeben, die 49 % seines vollständig verwässerten Stammkapitals entsprechen („Gegenleistungsaktien“). Aufteilung:

  • CAUD – 71,63 % der Gegenleistungsaktien (35,1 % von NYIAX auf vollständig verwässerter Basis)
  • Gregg Greenberg – 18,37 % (9 % von NYIAX vollständig verwässert)
  • 10 % werden als Rückbehaltungsaktien zur Schadensersatzsicherung treuhänderisch gehalten.
Es gibt keinen Barauszahlungserlös. Die Gegenleistungsaktien unterliegen (i) einer Sperrfrist von zwei Jahren oder 183 Tagen (je nachdem, was früher endet oder mit Zustimmung des NYIAX-IPO) und (ii) einer 10 %igen Schadensersatzrückbehaltung.

Wesentliche Vorschläge und Abstimmungsanforderungen. Die Aktionäre stimmen über (1) die Genehmigung des Tochtergesellschaftsverkaufs und (2) die Befugnis zur Vertagung der Versammlung zur Einholung weiterer Vollmachten ab, falls erforderlich. Vorschlag 1 erfordert die Zustimmung der Mehrheit aller ausstehenden CAUD-Stammaktien; Enthaltungen, Nichtabstimmungen und Broker-Non-Votes werden als „GEGEN“ gezählt. Vorschlag 2 erfordert die Mehrheit der abgegebenen Stimmen.

Strategische Begründung. Der Vorstand nennt anhaltende operative Verluste, begrenzten Kapitalzugang, überlappende Technologie mit NYIAX und die Möglichkeit, CAUD von BeOp- und DSL-Verbindlichkeiten zu entlasten und gleichzeitig durch eine Beteiligung an NYIAX Aufwärtspotenzial zu behalten. Der Vorstand empfiehlt einstimmig, beiden Vorschlägen "ZUZUSTIMMEN".

Hauptbedingungen. Der Abschluss ist für das dritte Quartal 2025 geplant und unterliegt umfangreichen gegenseitigen Zusicherungen, behördlichen und Drittzustimmungen, dem Fehlen wesentlicher nachteiliger Veränderungen und einer zufriedenstellenden Durchführung der Due Diligence. Die Vereinbarung enthält eine strenge No-Solicitation-Klausel und sieht übliche Kündigungsrechte vor, einschließlich eines Außerkrafttretensdatums am 31. Juli 2025. Die meisten Zusicherungen und Gewährleistungen gelten für zwei Jahre; Schadensersatzansprüche sind durch die 10 %ige Aktienrückbehaltung begrenzt.

Hervorgehobene Risiken. • Unsicherheit bei der Bewertung der illiquiden NYIAX-Aktien. • Kein sofortiger Geldzufluss zur Finanzierung der verbleibenden DLQ-Geschäfte. • Sperrfrist begrenzt Liquidität. • Das Scheitern der Aktionärszustimmung oder der Erfüllung der Abschlussbedingungen beendet das Geschäft und könnte die finanzielle Lage von CAUD beeinträchtigen. • CAUD verzichtet auf zukünftiges Aufwärtspotenzial von BeOp und DSL über seine indirekte Beteiligung an NYIAX hinaus.


Filed Pursuant to Rule 424(b)(3)

Registration No. 333-279771

PROSPECTUS SUPPLEMENT NO. 8

(to prospectus dated April 10, 2025)

Medicus Pharma Ltd.

1,115,500 Common Shares Issuable upon the Exercise of Warrants


This prospectus supplement amends and supplements the prospectus dated effective April 10, 2025, as supplemented or amended from time to time (the "Prospectus"), which forms a part of our Registration Statement on Form S-1 (Registration Statement No. 333-279771). This prospectus supplement is being filed to update and supplement the information included or incorporated by reference in the Prospectus with the information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 30, 2025 (the "Form 8-K"). Accordingly, we have attached the Form 8-K to this prospectus supplement.

This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

Our common shares and warrants, with an exercise price of $4.64 and expiration date of November 15, 2029 (the "Public Warrants"), are listed on The Nasdaq Capital Market ("Nasdaq") under the symbols "MDCX" and "MDCXW," respectively. On June 27, 2025, the last reported sales prices of the common shares and Public Warrants were $2.90 and $0.95, respectively.

We are an "emerging growth company" under applicable Securities and Exchange Commission rules and are eligible for reduced public company disclosure requirements.

Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading "Risk Factors" beginning on page 10 of the Prospectus, and under similar headings in any amendment or supplements to the Prospectus.

None of the Securities and Exchange Commission, any state securities commission or the securities commission of any Canadian province or territory has approved or disapproved of the securities offered by this prospectus supplement or the Prospectus or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is June 30, 2025.


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 29, 2025

MEDICUS PHARMA LTD.
(Exact name of registrant as specified in its charter)

Ontario 001-42408 98-1778211
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

300 Conshohocken State Road, Suite 200
Conshohocken, Pennsylvania, United States 19428
(Address of principal executive offices) (ZIP Code)

Registrant’s telephone number, including area code: (610) 540-7515

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class   Trading Symbols   Name of each exchange on which registered
Common shares, no par value   MDCX   NASDAQ Capital Market
Warrants, each exercisable for one common share at an exercise price of $4.64 per share   MDCXW   NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 1.01. Entry into a Material Definitive Agreement.

On June 29, 2025, Medicus Pharma Ltd. (“Medicus” or the “Company”), Antev Limited (“Antev”) and certain securityholders of Antev entered into a definitive securities exchange agreement (the “Definitive Agreement”), pursuant to which the Company has agreed to acquire (the “Transaction”) all of the issued and outstanding shares of Antev, on a fully diluted basis, in exchange for 2,666,600 (or approximately 17% in aggregate) of the issued and outstanding Medicus common shares (the “Consideration Shares”).

In addition to resale restrictions prescribed under applicable securities laws, the Consideration Shares will be subject to a staggered lock-up (including certain registration rights, as further described in the Definitive Agreement) and an agreement granting certain voting rights in favor of Company management for a period of 36 months.

Upon the achievement of certain milestones related to potential future U.S. Food and Drug Administration ("FDA") Phase 2 and New Drug Administration approvals, as more particularly described in the Definitive Agreement, Antev shareholders will be entitled to receive up to approximately US$65 million in additional contingent consideration.

The Transaction is expected to close before the end of August 2025, subject to the fulfillment of certain closing conditions, including obtaining Antev shareholder approval and other applicable corporate, regulatory and other third-party approvals. No assurances can be given that the parties will successfully close the Transaction on the terms or timeframe currently contemplated or at all. 

Antev is a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged prostate.

The foregoing description of the Definitive Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Definitive Agreement.

Item 8.01. Other Events.

On June 30, 2025, the Company issued a press release relating to, among other things, entry into the Definitive Agreement, as described in Item 1.01 above.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.   Description
2.1*   Share Exchange Agreement, dated June 29, 2025, by and between Medicus Pharma Ltd., Antev Limited and each of the securityholders of Antev Limited party thereto.
104.1 Cover Page Interactive Data File (embedded within the inline XBRL document). 

*   To be filed by amendment.


Forward Looking Statements

Certain information in this Current Report on Form 8-K constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the proposed Antev transaction and associated terms and timing thereof, the potential benefits of the Antev transaction, if consummated, including plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix, and the potential market opportunities related thereto. Forward-looking statements are often but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's annual report on form 10-K for the year ended December 31, 2024 (the "Annual Report"), and in the Company's other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this Current Report on Form 8-K are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Readers are cautioned that the foregoing list is not exhaustive, and readers are encouraged to review the Annual Report accessible on the Company's profile on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

  MEDICUS PHARMA LTD.
     
  By:   /s/ Raza Bokhari
  Name:   Dr. Raza Bokhari
  Title:   Executive Chairman and Chief Executive Officer

Dated: June 30, 2025​



FAQ

What are Collective Audience (CAUD) stockholders voting on?

Two proposals: (1) approve the sale of BeOp and DSL to NYIAX’s subsidiary in exchange for NYIAX stock and (2) allow adjournment to gather more proxies.

How many NYIAX shares will CAUD receive if the deal closes?

CAUD will receive 71.63% of the Consideration Shares, equal to 35.1% of NYIAX’s fully-diluted common stock.

Is there any cash component in the Subsidiary Sale?

No. The entire consideration consists of restricted NYIAX common stock; CAUD gains no immediate cash.

When is the transaction expected to close?

Management targets completion in Q3 2025, contingent on stockholder approval and other closing conditions.

What happens if stockholders do not approve the Subsidiary Sale?

The transaction will not proceed, and CAUD must seek alternative strategies; unvoted shares count as ‘AGAINST’.

Are appraisal rights available to CAUD stockholders?

No. Delaware law and CAUD’s charter do not provide appraisal or dissenters’ rights for this transaction.
Medicus Pharma Ltd

NASDAQ:MDCX

MDCX Rankings

MDCX Latest News

MDCX Latest SEC Filings

MDCX Stock Data

53.86M
8.82M
Pharmaceutical Preparations
W. CONSHOHOCKEN